Entacapone: Is it useful as complementary treatment with levodopa?;Entacapona: Es util como tratamiento complementario a la levodopa?

Revista de Neurologia

Volumn 28, Issue 8, 1999, Pages 817-834

  Burguera, Juan Andrés ^a  

^a Hospital Bellevue   (Spain)

Author keywords

Catechol O methyltransferase; Entacapone; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; ENTACAPONE; LEVODOPA; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE;

ARTICLE; COMBINATION CHEMOTHERAPY; DOPAMINE BRAIN LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HUMAN; PARKINSON DISEASE; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DOSE RESPONSE; DRUG COMBINATION; SPAIN;

ANTIPARKINSON AGENTS; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; PARKINSON DISEASE; SPAIN;

EID: 0033574342     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2808.99183     Document Type: Article

References (5)

1. Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytiramine) in gehirn des menschen und ihr verhalten bei erkrakungendes extrapyramidalen systems. Klin Wochenschr 1960; 38: 1236-9.
2. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths; 1987. p. 166-230.
3. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-81.
4. Fahn S. Adverse effects of levodopa in Parkinson's disease. In Calne DB, ed. Drugs for the treatment of Parkinson's disease. Berlin: Springer-Verlag; 1989. p. 385-409.
5. Nutt JG. Levodopa: rational and irrational pharmacology. Ann Neurol 1994; 36: 4-5.